Shares of CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN – Get Free Report) were down 1.9% on Monday. The stock traded as low as $3.45 and last traded at $3.56. 28,969 shares were traded during mid-day trading, a decline of 49% from the average session volume of 57,075 shares. The stock had previously closed at $3.63.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CollPlant Biotechnologies in a research note on Friday, September 4th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average price target of $120.00.
Read Our Latest Research Report on CLGN
CollPlant Biotechnologies Stock Down 4.6%
The firm has a market cap of $7.00 million, a PE ratio of -0.27 and a beta of 1.77. The company’s fifty day moving average price is $3.59 and its two-hundred day moving average price is $3.64.
CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) last issued its quarterly earnings results on Wednesday, September 30th. The company reported ($1.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.45) by $0.56. The business had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.48 million. CollPlant Biotechnologies had a negative net margin of 678.37% and a negative return on equity of 298.21%.
CollPlant Biotechnologies Company Profile
CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is an Israel-based biotechnology company developing regenerative medicine products and tissue-engineering technologies. The company’s platform uses genetically engineered tobacco plants to produce recombinant human collagen (rhCollagen), a purified collagen material designed to support the repair, replacement, and regeneration of human tissue.
CollPlant develops rhCollagen-based products for applications including 3D bioprinting, tissue engineering, and advanced wound care.
Featured Stories
- Five stocks we like better than CollPlant Biotechnologies
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
- Synchrony Aces The Quarter As Credit Fears Fade
Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
